Cypherpunk Technologies (CYPH) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual meeting scheduled for June 18, 2025, to be held virtually at 11:30 AM local time.
Shareholders can access proxy materials and vote electronically using a control number.
Proxy materials include the annual report for the year ended December 31, 2024, and the 2025 proxy statement.
Voting matters and shareholder proposals
Election of three nominees to the Board of Directors.
Advisory vote on the compensation of named executive officers.
Ratification of EisnerAmper LLP as independent registered public accounting firm for fiscal year 2025.
Board recommends voting "FOR" all proposals.
Board of directors and corporate governance
Three individuals nominated for election to the Board of Directors.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Cypherpunk Technologies
- Returned to profitability in 2025 with strong ZEC gains, new capital, and clinical progress.CYPH
Q4 202516 Mar 2026 - Phase 2 trials for DKN-01 in gastric and colorectal cancer near key data readouts and expansion.CYPH
Piper Sandler 36th Annual Healthcare Conference11 Jan 2026 - Sirexatamab shows strong efficacy in GI cancer trials; FL-501 advances toward clinical studies.CYPH
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - Sirexatamab improved response rates in CRC, especially in DKK1-high and VEGF-naive patients.CYPH
Study Result9 Jan 2026 - Shareholders approved key proposals including share increase, reverse split, and new equity plan.CYPH
AGM 202515 Dec 2025 - Virtual meeting to elect directors, approve pay, and ratify auditor, with strong governance.CYPH
Proxy Filing2 Dec 2025 - Stockholders to vote on key capital, governance, and compensation proposals; Board urges approval.CYPH
Proxy Filing2 Dec 2025 - Stockholders will vote on key capital structure changes and equity plans at a virtual meeting.CYPH
Proxy Filing2 Dec 2025 - Sirexatamab delivers higher response rates and PFS in key colorectal cancer subgroups.CYPH
Status Update24 Nov 2025